4547:TYO
Kissei Pharmaceutical Co Ltd
Â¥3,810.00
arrow_upward
+1.33%(+50.00) 1D
Oct 15, 3:30:00 PM GMT+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4547...
Open
Â¥3,795
High
Â¥3,820
Low
Â¥3,760
Mkt. cap
177.32B
Avg. vol.
69.28K
Volume
64.80K
Dividend
3.15%
Quarterly dividend
Â¥30
Ex-dividend date
Sep 29, 2026
P/E ratio
11.29
52-wk high
Â¥5,040
52-wk low
Â¥3,500
EPS
Â¥337
Shares outstanding
46.72M
No. of employees
2K
Open
Â¥3,795
High
Â¥3,820
Low
Â¥3,760
Mkt. cap
177.32B
Avg. vol.
69.28K
Volume
64.80K
Dividend
3.15%
Quarterly dividend
Â¥30
Ex-dividend date
Sep 29, 2026
P/E ratio
11.29
52-wk high
Â¥5,040
52-wk low
Â¥3,500
EPS
Â¥337
Shares outstanding
46.72M
No. of employees
2K
News stories
From web sources and news partners
TradingView
·
1 hour ago
TruGolf Holdings (NASDAQ: TRUG) Taps Newly Acquired Polymath to Tokenize Franchise Ownership Records
Yahoo Finance
·
1 hour ago
Dr. Calvin Choi on TGE's NYSE Listing and Global SPAC Strategy
The Mighty 790 KFGO
·
7 minutes ago
Nasdaq reports network disruption, US equities data feeds impacted
Seeking Alpha
·
23 minutes ago
Midday Markets Need to Know: Ukraine flags Starlink curbs, Fed rate hike odds fall, and more (SP500:)
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees1.79K
FoundedAug 9, 1946
HeadquartersMatsumoto, Nagano, Japan
SectorPharmaceutical industry
Websitekissei.co.jp